FOR IMMEDIATE RELEASE
July 29, 2025
Contact:
Andarix Pharmaceuticals
617-957-9858
info@andarix.com
Driving New Partnerships and Investment Opportunities in Precision Oncology Radiopharmaceuticals
Boston — At the 4th Targeted Radiopharmaceuticals Summit US, Andarix Pharmaceuticals is showcasing its pioneering targeted radiopharmaceutical technology for treating lung and pancreatic cancer. Company leadership is presenting recent data demonstrating how Andarix’s proprietary peptide-based platform delivers radioisotopes directly to tumors, aiming to improve outcomes in these hard-to-treat cancer types.
Highlights for potential partners and investors include:
Precision Targeting: Andarix’s technology utilizes engineered somatostatin analogs to selectively bind to overexpressed receptors on tumor cells in lung and pancreatic cancers.
Pipeline Momentum: New results from IND-enabling and early clinical studies reveal high tumor uptake, a favorable safety profile, and the potential for theranostic use—enabling both imaging and therapy.
Strategic Partnerships: Andarix seeks collaborations in clinical development, isotope supply, CDMO alliances, companion diagnostics, and commercial distribution to accelerate global access.
Investor discussions focus on the differentiated nature of Andarix’s radiopharma platform, its strong intellectual property position, and compelling early data, underscoring significant opportunity for further validation and growth within the radiopharmaceutical space.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is an emerging leader in the development of targeted radiopharmaceutical therapies for cancer. The company’s proprietary technology harnesses novel somatostatin peptide conjugates designed to deliver therapeutic and diagnostic radioisotopes directly to tumors, with an initial focus on addressing urgent needs in lung and pancreatic cancer.